EP1144390A2 - Kinase inhibitors - Google Patents

Kinase inhibitors

Info

Publication number
EP1144390A2
EP1144390A2 EP00905700A EP00905700A EP1144390A2 EP 1144390 A2 EP1144390 A2 EP 1144390A2 EP 00905700 A EP00905700 A EP 00905700A EP 00905700 A EP00905700 A EP 00905700A EP 1144390 A2 EP1144390 A2 EP 1144390A2
Authority
EP
European Patent Office
Prior art keywords
coor
aryl
alkenyl
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00905700A
Other languages
German (de)
French (fr)
Inventor
David M. Armistead
Jean E. Bemis
Daniel Elbaum
Gregory Habgood
Perry M. Novak
Joseph J. Nunes
Leticia M. Toledo-Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP1144390A2 publication Critical patent/EP1144390A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Definitions

  • the invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions.
  • the inhibitors and compositions comprising them are useful for treating or modulating disease in which kinases may be involved, symptoms of such disease, or the effect of other physiological events mediated by kinases.
  • the invention also provides for methods of making kinase inhibitor compounds and methods for treating diseases in which kinase activity is involved.
  • the protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a wide variety of signal transduction processes within the cell. (See, Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book, I and II, Academic Press, San Diego, CA).
  • Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The kinases may be categorized into families by the substrates they phosphorylate (e.g., protein- tyrosine, protein-serine/threonine, lipids, etc.).
  • cAPK cAMP-dependent protein kinase
  • the N-terminal portion forms the small lobe (including subdomains I-IV) whose architecture is composed of an antiparallel five-strand ⁇ -sheet and one ⁇ -helix, while the lower C- terminal domain forms another lobe (including subdomains VIA - XI) containing mostly -helical architecture.
  • Subdomain V spans the two lobes.
  • the N-terminal domain is thought to participate in orienting the nucleotide (or other binding entity), while the C- terminal domain is thought to be responsible for binding peptide substrate and initiating phosphotransfer to the hydroxyl group of a serine, threonine, or tyrosine residue.
  • the N- and C-terminal domains are connected through a single peptide strand, to which the adenine moiety of ATP binds via an eleven membered hydrogen bond cycle, involving the NI and the N6 amino group, and the backbone carbonyl and NH functions of two nonconsecutive residues.
  • This linker acts as a hinge about which the domains can rotate with respect to each other without disruption of the secondary architecture of the kinase. Several torsion angle changes in the linker backbone allow this movement to occur.
  • the ribose group of ATP is anchored to the enzyme via hydrogen bonds with residues within the ribose-binding pocket.
  • the triphosphate group is held in position via various polar interactions with several variable residues form the glycine rich loop, the conserved DFG motive and the catalytic loop.
  • Protein kinases may be characterized by their regulation mechanisms. It must be noted, however, that an individual protein kinase may be regulated by more than one mechanism. These mechanisms include, for example, autophosphorylation, transphosphorylation by other kinases, protein-protein interactions, protein-lipid interactions, and protein-polynucleotide interactions.
  • Kinases regulate many different cell processes including, but not limited to, proliferation, differentiation, apoptosis, motility, transcription, translation and other signaling processes, by adding phosphate groups to target proteins. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein biological function. Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc.
  • the appropriate protein kinase functions in signaling pathways to activate or inactivate (either directly or indirectly), for example, a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.
  • Uncontrolled signaling due to defective control of protein phosphorylation has been implicated in a number of diseases, including, for example, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system, and angiogenesis.
  • Initial interest in protein kinases as pharmacological targets was stimulated by the findings that many viral oncogenes encode structurally modified cellular protein kinases with constitutive enzyme activity. These findings pointed to the potential involvement of proto-oncogene encoded protein kinases in human proliferative disorders.
  • deregulated protein kinase activity resulting from a variety of more subtle mechanisms, has been implicated in the pathophysiology of a number of important human disorders including cancer and immunologically related diseases.
  • the development of selective protein kinase inhibitors that can block the disease pathologies and/or symptoms resulting from aberrant protein kinase activity has therefore generated much interest.
  • the invention relates to compounds of the formula:
  • R 1 is H; CN; COOR 5 ; C(O)NRV; halo; C1-C10 alkyl; C1-C10 alkenyl;
  • X is O or S; and the remaining groups are as defined herein.
  • the invention also relates to compositions comprising these compounds, methods of making these compounds, methods of inhibiting enzyme activity, particularly kinase activity, through use of these compounds, and methods of treating disease or disease symptoms in a mammal, particularly where modulation of enzyme activity, and more particularly kinase activity, can affect disease outcome.
  • the invention provides compounds useful in inhibiting kinase activity and inhibiting kinases or other polypeptides having sequences or subsequences homologous to kinase sequences or subsequences.
  • the inhibitory compound has the
  • R 1 is H; CN; COOR 5 ; C(O)NR 5 R 5 ; halo; C1-C10 alkyl; C1-C10 alkenyl; C1-C10 alkyl substituted with 1-3 independent NR R , NR R , SR or OR ; or C1-C10
  • R is phenyl substituted with 1-3 independent R ; R ; COOR ; or C1-C10
  • Each R is independently selected from H, C1-C10 alkyl; C2-C10 alkenyl;
  • NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5 ; NR 5 S(O)2R 8 ;
  • R or C1-C10 alkenyl substituted with aryl, R or R ;
  • Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
  • Each R is independently C(O)R , COOR , or S(O)2 R ;
  • Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substiruent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
  • NR 6 R 6 COOR 5 ; NO2; CN; C(O)R 5 ; C(O)NR 5 R 5 ; C1-C10 alkyl substituted with 1-3
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; NR R ;
  • Each R is independently H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; Cl-ClO alkyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR 13 , SR°, NR B R 13 , COOR* 3 , NO2, CN, C(O)R' , C(O)NR R , NHC(O)R 3 , or OC(O)R 3 ; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalky
  • Each R is independently C(O)R , COOR , or S(O)2R ;
  • Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
  • Each R 15 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with 1-3
  • Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
  • Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group; and
  • Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R 9 ; halo; haloalkyl CF3; OR 12 ; SR 12 ; NR 12 R 12 ; COOR 12 ; NO2; CN; C(O)R 12 ; C(O)C(O)R 12 ; C(O)NR'V 2 S(O)2R 12 ; N(R l2 )C(O)R
  • R 1 is H; COOR 5 ; C(O)NR 5 R 5 ; halo; C2-C10 alkyl; Cl-ClO alkenyl; Cl- CIO alkyl substituted with NR R , NR R , SR or OR ; or Cl-ClO alkenyl substituted with NR R , NR R , SR or OR ;
  • R is phenyl substituted with 1-3 independent R ; R ; COOR ; or Cl-ClO
  • Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
  • Each R 5 is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently C(O)R , COOR , or S(O)2 R ;
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
  • R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
  • Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C 1 -C 10 alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl, C3 -C 10 cycloalkyl, C4-
  • Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
  • Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
  • Each R 1 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10
  • Each R is independently H; C1 -CIO alkyl; C3-C 10 cycloalkyl or phenyl;
  • Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl CF3; OR 12 ; SR 12 ; NR 12 R 12 ; COOR 12 ; NO2; CN; C(O)R 12 ; C(O)C(O)R 12 ; C(O)NR' 2 R 12 S(O)2R 12 ; N(R l2 )C(O)R 12 ; N(R I2 )(COOR 12 ); N(R' 2 )S(O)2R 12 ; S(O)2NR* 2 R' 2 OC(O)R 12 ; NR l 2 C(O)NR 12 R 12 ; NR 12 C(O)C
  • R 1 is CN
  • X is O or S
  • Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl CF3; SR 5 ; OR 5 ; NR 5 R 5 ; NRV; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 OC(O)R 5 ; S(O)2R 5 ; S(O)2NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R " NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR $ S(O)2R 5 ; NR
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R 6 is independently C(O)R , COOR , or S(O)2 R 5 ;
  • Each R is independently halo, CF3, SR , OR , OC(O)R , NR R , NR'V ', NR 1 R 11 , COOR 10 , NO2, CN, C(O)R'°, or C(O)NR 10 R 10 ;
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- CIO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
  • Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10
  • Each R is independently C(O)R , COOR , or S(O)2R ;
  • Each R 12 is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted
  • Each R is each independently selected from Cl-ClO alkyl; C2-C10
  • Each R 15 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
  • Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR 5 ; OR 5 ; NR 5 R 5 ; NR 5 R 6 ; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 ; OC(O)R 5 ; S(O)2R 5 ; S(O)2NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR $ C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(
  • Each R is independently H; C 1 -C 10 alkyl; C3-C 10 cycloalkyl or phenyl;
  • Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
  • Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl
  • R may not be Me, Cl, or OMe
  • each R is independently selected from C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R 8 ; I; Br; F; CF 3 ; SR 5 ; OR 25 ; NR 5 R 5 ; NR 5 R 6 ; COOR 5 ; NO 2 ; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 ; S(O) 2 NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 8 ; NR 5 S(O) 2 NR 5 R 5 ; NR 5 S(O) 2 R 5 ; NR 5 S(O) 2 R 5 ; NR 5 S(O) 2 R 5 ; NR 5 S(O) 2 R 5
  • the compound has the formula directly above wherein each R is independently selected from NR 5 R 5 ; NRV; NR C(O)NR R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5 ; NR 5 S(O)2R 8 ; NR C(O)C(O)NR R ; or NR C(O)C(O)NR R .
  • the compound is independently selected from NR 5 R 5 ; NRV; NR C(O)NR R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5 ; NR
  • 4 17 is of any of the formulae above, wherein at least two of R and or R are independently H. Preferred compounds of these embodiments are also those wherein X is O. In an alternate embodiment, the inhibitory compound has the formula:
  • R is CN
  • X is O or S
  • Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl CF3; SR 5 ; OR 5 ; NR 5 R 5 ; NR 5 R 6 ; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 OC(O)R 5 ; S(O)2R 5 ; S(O)2NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R
  • R or Cl-ClO alkenyl substituted with aryl, R or R ;
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently C(O)R , COOR , or S(O)2 R ;
  • Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
  • NR R NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR 6 R 6 ; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; COOR 10 ; NO2; CN; C(O)R 10 ; or C(O)NR 10 R'°; Each R is independently H, Cl-Cl
  • Each R is independently C(O)R , COOR , or S(O)2R ;
  • Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR 13 , SR B , NR' 3 , COOR 13 , NO2, CN, C(O)R°, C(O)NR 13 R 13 , NHC(O)R 13 , or OC(O)R 13 ;
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl
  • Each R is independently selected from Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR 5 ; OR 5 ; NR 5 R 5 ; NRV; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 ; OC(O)R 5 ; S(O)2R 5 ; S(O)2NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5
  • Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
  • Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
  • Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
  • Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl;
  • R 9 halo, CF3, OR 12 , SR 12 , NR' 2 , COOR 12 , NO2, CN, C(O)R 12 , C(O)NR 12 R 12 ,
  • NHC(O)R 12 NH(COOR 12 ), S(O)2NR 12 R 12 , OC(O)R 12 ; C2-C10 alkenyl substituted with
  • each R 14 is independently selected from C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R 8 ; halo; CF 3 ; SR 5 ; OR 25 ; NR 5 R 5 ; NR 5 R 6 ; COOR 5 ; NO 2 ; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 ; S(O) 2 NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 8 ; NR 5 S(O) 2 NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 8 ; NR 5 S(O) 2
  • each R 25 is independently H; C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R 9 ; Cl-ClO alkyl substituted with one or two
  • each R is independently selected from NRV; NR 5 R 6 ; NR 5 C(O)NRV; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NRV; NR 5 S(O)2R 5 ; NR 5 S(O)2R 8 ;
  • the inhibitory compound has the formula
  • R is CN
  • X is O or S
  • Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently C(O)R , COOR , or S(O)2 R ;
  • Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- CIO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; 10 10 10 10 10 10 11 1 1 1 1 1 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; COOR 10 ; NO2; CN; C(O)R'°; or C(O)NR" V°
  • Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10
  • Each R is independently C(O)R , COOR , or S(O)2R ;
  • Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- CIO cycloalkenyl, halo, CF3, OR 13 , SR 13 , NR 13 R 13 , COOR 13 , NO2, CN, C(O)R 13 , C(O)NR ,3 R 13 , NHC(O)R 13 , or OC(O)R 13 ;
  • Each R is independently selected from C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR 5 ; OR 5 ; NR 5 R 5 ; NRV; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)C(O)R 5 ; C(O)NR 5 R 5 ; OC(O)R 5 ; S(O)2R 5 ; S(O)2NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5
  • Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted 7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10
  • Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo haloalkyl; CF3; SR 5 ; OR 5 ; NR 5 R 5 ; NRV; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)C(O)R 5 C(O)NR 5 R 5 ; OC(O)R 5 ; S(O)2R 5 ; S(O)2NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 NR 5 C(O)R 5 ; NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5 ;
  • Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
  • Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
  • Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl;
  • Preferred compounds of this embodiment are also those wherein X is O.
  • the compound has the formula directly above wherein each R 17 is independently selected from from H, Cl-ClO alkyl C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R 8 ; I; Br; F; CF 3 ; SR 5 ; OR 5 ; NR 5 R 5 ; NR 5 R 6 ; COOR 5 ; NO 2 ; CN; C(O)R 5 ; C(O)C(O)R C(O)NR 5 R 5 ; S(O) 2 NR 5 R 5 ; NR 5 C(O)NR 5 R 5 ; NR 5 C(O)C(O)R 5 ; NR 5 C(O)R !
  • each R is independently selected from NR R ; NR R ; NR C(O)NR R 5 ; NR C(O)C(O)R ;
  • NR 5 C(O)R 5 NR 5 (COOR 5 ); NR 5 C(O)R 8 ; NR 5 S(O)2NR 5 R 5 ; NR 5 S(O)2R 5 ; NR 5 S(O)2R 8 ; NR C(O)C(O)NR R ; or NR C(O)C(O)NR R .
  • 4 17 is of any of the formulae above, wherein at least two of R and or R are independently H. Preferred compounds of these embodiments are also those wherein X is O. In another embodiment, the inhibitory compound has the formula,
  • R is CN
  • NR -NR C(O)NR R NR -NR R ; NR -NR R ; Cl-ClO alkyl substituted with aryl, R , halo, CF3, SR 5 , OR 5 , OC(O)R 5 , NR 5 R 5 , NR 5 R 6 , COOR 5 , NO2, CN, C(O)R 5 ,
  • R is R ; COOR ; or Cl-ClO alkyl substituted with R , R , or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, R 9 , halo, CF3, OR 12 , SR 12 , NR I 2 R 12 , COOR* 2 , NO2, CN, C(O)R 12 , C(O)NR 12 R 12 , NHC(O)R 12 , NH(COOR 12 ), S(O)2NR l 2 R 12 , OC(O)R 12 , Cl-ClO alkyl substituted with R 9 , halo, CF3, OR 12 , SR 12 , NR 12 R 12 , COOR 12 , NO2, CN, C(O)R 12 , C(O)NR 12 R 12 , N
  • R is not unsubstituted furanyl, unsubstituted thienyl or unsubstituted pyridyl;
  • X is O or S;
  • Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently C(O)R , COOR , or S(O)2 R ;
  • Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; NR R ;
  • Each R is independently C(O)R , COOR , or S(O)2R ;
  • Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally
  • Each R 1 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10
  • Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl CF3; OR* 2 ; SR 12 ; NR' 2 ; COOR 12 ; NO2; CN; C(O)R 12 ; C(O)C(O)R 12 ; C(O)NR 12 R 12 S(O)2R 12 ; N(R 12 )C(O)R 12 ; N(R 12 )(COOR 12 ); N(R 12 )S(O)2R 12 ; S(O)2NR 12 R i 2 OC(O)R 12 ; NR l2 C(O)NR 12 R 12 ; NR l C(O)C(O)R
  • R is R that is attached by a nitrogen atom in the R ring system.
  • Preferred compounds of these embodiments are also those wherein X is O.
  • the inhibitory compound has the formula,
  • R is one, two, or three substituents, each independently selected from H,
  • Each R 5 is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
  • Each R is independently C(O)R , COOR , or S(O)2 R ; 7 10 10 10 10 10
  • NR R NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NRV; COOR 5 ; NO2; CN; C(O)R 5 ; C(O)NR 5 R
  • Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl-
  • Each R 10 is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR* 3 , SR 13 , NR' 3 , COOR 13 , NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alken
  • Each R is independently C(O)R , COOR , or S(O)2R ;
  • Each R 1 is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted
  • Each R is independently Cl-ClO alkyl or both R may be taken together
  • Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
  • this invention relates to a method of treating disease or disease symptoms, particularly kinase mediated disease or disease symptoms, in a mammal comprising the step of administering to said mammal a compound, or a composition comprising a compound, of any of the formulae described herein.
  • a mammal is a human.
  • this invention relates to a method of treating disease or disease symptoms in a mammal comprising the step of administering to said mammal a compound, or a composition comprising a compound, of any of the formulae described herein.
  • the mammal is a human.
  • halo refers to any radical of fluorine, chlorine, bromine or iodine.
  • alkyl alkenyl
  • alkynyl hydrocarbon chains that may be straight-chain or branched-chain, containing the indicated number of carbon atoms.
  • Cl-ClO indicates the group may have from 1 to 10 (inclusive) carbon atoms in it.
  • ring and “ring system” refer to a ring comprising the delineated number of atoms, said atoms being carbon or, where indicated, a heteroatom such as nitrogen, oxygen or sulfur. The ring itself, as well as any substitutents thereon, may be attached at any atom that allows a stable compound to be formed.
  • Kinases include, for example, protein kinases, lipid kinases (e.g., phosphatidylinositol kinases PI-3, PI-4) and carbohydrate kinases. Further information relating to kinase structure, function and and their role in disease or disease symptoms is available at the Protein Kinase Resource web site (http : //www . sdsc . edu/Kinases/pk home . tml ) . Kinases may be of prokaryotic, eukaryotic, bacterial, viral, fungal or archaea origin.
  • the compounds and compositions of the invention are therefore also particularly suited for treatment of diseases and disease symptoms that involve one or more of the aforementioned protein kinases.
  • the compounds, compositions or methods of this invention are particularly suited for inhibition of or treatment of disease or disease symptoms mediated by LCK, ZAP, LYN, EGFR, ERB-B2, KDR, ITK, BTK, or SYK.
  • the compounds, compositions or methods of this invention are particularly suited for inhibition of or treatment of disease or disease symptoms mediated by src-family kinases.
  • the compounds, compositions or methods of this invention are particularly suited for inhibition of or treatment of disease or disease symptoms mediated by kinases in one of the kinase families defined by Hardie & Hanks, ed. supra.
  • the compounds and compositions are also suited for regulating or modulating signal transduction in signal transduction pathways that involve one or more kinases, thus affecting events in a cell, and are therefor useful in methods for regulating or modulating signal transduction.
  • the inhibitors described herein are also useful for inhibiting the biological activity of any enzyme comprising greater than 90%, alternatively greater than 85%, or alternatively greater than 70% sequence homology with a kinase sequence, including the kinases mentioned herein.
  • the inhibitors described herein are also useful for inhibiting the biological activity of any enzyme comprising a subsequence, or variant thereof, of any enzyme that comprises greater than 90%, alternatively greater than 85%, or alternatively greater than 70% sequence homology with a kinase subsequence, including subsequences of the kinases mentioned herein.
  • Such subsequence preferably comprises greater than 90%, alternatively greater than 85%, or alternatively greater than 70% sequence homology with the sequence of an active site or subdomain of a kinase enzyme.
  • the subsequences, or variants thereof comprise at least about 300, or alternatively at least about 200, amino acids.
  • the inhibitors described herein are useful for inhibiting the biological activity of any enzyme that binds ATP and thus for treating disease or disease symptoms mediated by any enzyme that binds ATP.
  • the inhibitors described herein are also useful for inhibiting the biological activity of any enzyme that is involved in phosphofransfer and thus for treating disease or disease symptoms mediated by any enzyme that is involved in phosphotransfer.
  • the inhibitors described herein are also useful for inhibiting the biological activity of a polypeptide or enzyme having sequence homology with a kinase sequence and thus for treating disease or disease symptoms mediated by such polypeptide or enzyme.
  • polypeptides or enzymes may be identified by comparison of their sequence with kinase sequences and kinase catalytic domain sequences. For example, one method of comparison involves the database PROSITE (http://expasy.hcuge.ch), containing "signatures” or sequence patterns (or motifs) or profiles of protein families or domains.
  • inhibitors described herein are useful for inhibiting the biological activity of a polypeptide or enzyme comprising a sequence that comprises a "signature" or sequence pattern or profile derived for, and identified in PROSITE as relating to kinases, and for treating disease or disease symptoms mediated by such polypeptide or enzyme.
  • PROSITE motifs or consensus patterns identified as relating to kinases include PS00107, PS00108, PS00109, PS50011, PS00915, and PS00916.
  • kinase mediated diseases are those wherein a protein kinase is involved in signaling, mediation, modulation, or regulation of the disease process.
  • Kinase mediated diseases are exemplified by the following disease classes: cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, angiogenesis, neovascularization, vasculogenesis, cardiovascular, and the like.
  • the inhibitors described herein are useful for crystallizing or co-crystallizing with a protein kinase.
  • Such crystals or crystal complexes may additionally comprise additional peptides and or metal ions.
  • the crystals or crystal complexes may be used for investigation and determination of enzyme characteristics including, for example, structure of the kinase enzyme, enzyme active site domains, and inhibitor-enzyme interactions. This information is useful in developing inhibitor compounds with modified characteristics and for understanding structure-function relationships of the enzymes and their enzyme-inhibitor interactions.
  • the inhibitory compounds described herein may be used as platforms or scaffolds which may be utilized in combinatorial chemistry techniques for preparation of derivatives and/or chemical libraries of compounds.
  • Such derivatives and libraries of compounds have kinase inhibitory activity and are useful for identifying and designing compounds possessing kinase inhibitory activity.
  • Combinatorial techniques suitable for utilizing the compounds described herein are known in the art as exemplified by Obrecht, D.
  • tags or identifier or labeling moieties may be attached to and/or detached from the compounds of the formulae herein or their derivatives, to facilitate tracking, identification or isolation of the desired products or their intermediates.
  • moieties are known in the art.
  • the chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. Examples of such chemicals are those that appear in the various synthetic and protecting group chemistry texts and treatises referenced herein.
  • a "pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention.
  • Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
  • Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
  • an appropriate benzaldehyde (SI) is converted to pyrimidinone S2 by reaction with an appropriate cyanoacetate (or equivalent) S- methylisothiouronium sulphate.
  • Pyrimidinone S2 may be reacted with a substituted aniline or amine to form pyrimidinone S3.
  • a protected benzaldehyde (S4) may be reacted under the same conditions to provide pyrimidinone S5.
  • Pyrimidinone S5 can be subsequently reacted with an aniline, amine or other appropriate heteroatom nucleophile to provide pyrimidinone S6.
  • novel compounds of the present invention are excellent ligands for protein kinases, subsequences thereof, and homologous polypeptides. Accordingly, these compounds are capable of targeting and inhibiting kinase enzyme and subsequences thereof. Inhibition can be measured by various methods, including, for example, those methods illustrated in the examples below.
  • the compounds described herein may be used in assays, including radiolabelled, antibody detection and fluorometric, for the isolation, identification, or structural or functional characterization of enzymes, peptides or polypeptides.
  • the compound(s) are tested for activity in cellular assays of allergic mediator release.
  • the receptor-induced degranulation in mast cells or basophils leading to histamine release and the production of cytokines is a useful measure.
  • This assay is performed similarly to techniques described in the literature (3), and involves crosslinking of antigen-specific IgE on cells leading to degranulation and or cytokine production.

Abstract

The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

Description

KINASE INHIBITORS
This application claims priority benefit under Title 35 USC § 119(e) of United States Provisional Application No. 60/116,697, filed January 22, 1999, and entitled Kinase Inhibitors, the entire contents of which are incorporated herein by reference.
Background of the Invention
The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating or modulating disease in which kinases may be involved, symptoms of such disease, or the effect of other physiological events mediated by kinases. The invention also provides for methods of making kinase inhibitor compounds and methods for treating diseases in which kinase activity is involved. The protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a wide variety of signal transduction processes within the cell. (See, Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book, I and II, Academic Press, San Diego, CA). Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The kinases may be categorized into families by the substrates they phosphorylate (e.g., protein- tyrosine, protein-serine/threonine, lipids, etc.). Sequence motifs have been identified that generally correspond to each of these kinase families (See, for example, Hanks, S.K., Hunter, T., FASEB J., 9:576-596 (1995); Knighton et al., Science, 253:407-414 (1991); Hiles et al., Cell, 70:419-429 (1992); Kunz et al., Cell, 73:585-596 (1993); Garcia-Bustos et al., EMBOJ., 13:2352-2361 (1994)).
Since the structure of the catalytic subunit of cAMP-dependent protein kinase (cAPK) was elucidated, approximately two dozen additional kinase structures have been solved as either apo enzymes or binary and ternary complexes (with ATP, ATP analogs, metal ions, ADP, ATP competitive inhibitors in the absence or presence of peptide substrate or peptide inhibitors). These proteins share a structurally conserved catalytic domain comprising two lobes that can be further subdivided into twelve subdomains. The N-terminal portion forms the small lobe (including subdomains I-IV) whose architecture is composed of an antiparallel five-strand β-sheet and one α-helix, while the lower C- terminal domain forms another lobe (including subdomains VIA - XI) containing mostly -helical architecture. Subdomain V spans the two lobes. The N-terminal domain is thought to participate in orienting the nucleotide (or other binding entity), while the C- terminal domain is thought to be responsible for binding peptide substrate and initiating phosphotransfer to the hydroxyl group of a serine, threonine, or tyrosine residue.
The N- and C-terminal domains are connected through a single peptide strand, to which the adenine moiety of ATP binds via an eleven membered hydrogen bond cycle, involving the NI and the N6 amino group, and the backbone carbonyl and NH functions of two nonconsecutive residues. This linker acts as a hinge about which the domains can rotate with respect to each other without disruption of the secondary architecture of the kinase. Several torsion angle changes in the linker backbone allow this movement to occur. The ribose group of ATP is anchored to the enzyme via hydrogen bonds with residues within the ribose-binding pocket. The triphosphate group is held in position via various polar interactions with several variable residues form the glycine rich loop, the conserved DFG motive and the catalytic loop.
Protein kinases may be characterized by their regulation mechanisms. It must be noted, however, that an individual protein kinase may be regulated by more than one mechanism. These mechanisms include, for example, autophosphorylation, transphosphorylation by other kinases, protein-protein interactions, protein-lipid interactions, and protein-polynucleotide interactions.
Kinases regulate many different cell processes including, but not limited to, proliferation, differentiation, apoptosis, motility, transcription, translation and other signaling processes, by adding phosphate groups to target proteins. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein biological function. Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc. The appropriate protein kinase functions in signaling pathways to activate or inactivate (either directly or indirectly), for example, a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor. Uncontrolled signaling due to defective control of protein phosphorylation has been implicated in a number of diseases, including, for example, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system, and angiogenesis. Initial interest in protein kinases as pharmacological targets was stimulated by the findings that many viral oncogenes encode structurally modified cellular protein kinases with constitutive enzyme activity. These findings pointed to the potential involvement of proto-oncogene encoded protein kinases in human proliferative disorders. Subsequently, deregulated protein kinase activity, resulting from a variety of more subtle mechanisms, has been implicated in the pathophysiology of a number of important human disorders including cancer and immunologically related diseases. The development of selective protein kinase inhibitors that can block the disease pathologies and/or symptoms resulting from aberrant protein kinase activity has therefore generated much interest.
Summary of he: Invention
The invention relates to compounds of the formula:
wherein , R1 is H; CN; COOR5; C(O)NRV; halo; C1-C10 alkyl; C1-C10 alkenyl;
5 5 5 6 5 5
C1-C10 alkyl substituted with 1-3 independent NR R , NR R , SR or OR ; or C1-C10
5 5 5 6 5 5 alkenyl substituted with 1-3 independent NR R , NR R , SR or OR ;
R2 is NRV; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R15; NR5-NR5R6; C1-C10 alkyl substituted with 1-3 independent aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NRV, NR5R , COOR5, NO2, CN, C(O)R5, C(O)NRV, or S(O)2NR5R5; or C1-C10 alkenyl substituted with 1-3 independent aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5; R is phenyl substituted with 1-3 independent R ; R ; COOR ; or C1-C10
7 8 alkyl substituted with 1-3 independent aryl, R or R ;
X is O or S; and the remaining groups are as defined herein.
The invention also relates to compositions comprising these compounds, methods of making these compounds, methods of inhibiting enzyme activity, particularly kinase activity, through use of these compounds, and methods of treating disease or disease symptoms in a mammal, particularly where modulation of enzyme activity, and more particularly kinase activity, can affect disease outcome.
Detailed Description of the Invention
The invention provides compounds useful in inhibiting kinase activity and inhibiting kinases or other polypeptides having sequences or subsequences homologous to kinase sequences or subsequences. In one embodiment, the inhibitory compound has the
formula:
wherein,
R1 is H; CN; COOR5; C(O)NR5R5; halo; C1-C10 alkyl; C1-C10 alkenyl; C1-C10 alkyl substituted with 1-3 independent NR R , NR R , SR or OR ; or C1-C10
5 5 5 6 5 5 alkenyl substituted with 1-3 independent NR R , NR R , SR or OR ;
R2 is NR5R5; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R15; NR5-NRV; C1-C10 alkyl substituted with 1-3 independent aryl, R , halo, CF3, SR , OR , OC(O)R , NR R , NR R , COOR , NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NRV; or C1-C10 alkenyl substituted with 1-3 independent aryl, R , halo, CF3, SR , OR5, OC(O)R5, NR R , NR R , COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR¥;
3 4 8 5
R is phenyl substituted with 1-3 independent R ; R ; COOR ; or C1-C10
7 8 alkyl substituted with 1-3 independent aryl, R or R ; X is O or S;
4
Each R is independently selected from H, C1-C10 alkyl; C2-C10 alkenyl;
8 C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl;
CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5;
NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8;
NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; C1-C10 alkyl substituted with aryl, R? or
8 7 8
R ; or C1-C10 alkenyl substituted with aryl, R or R ;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
7 9 with 1-3 independent aryl, R or R groups; C3-C10 cycloalkyl substituted with 1-3
7 9 independent aryl, R or R groups; or C1-C10 alkenyl substituted with 1-3 independent
7 9 aryl, R or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10 Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
NR'V ', NR* V ', COOR10, NO2, CN, C(O)R'°, or C(O)NR10R10 ; g
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substiruent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with 1-3
7 9 7 9 independent R , R or aryl; or C1-C10 alkenyl substituted with 1-3 independent R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
COOR10; NO2; CN; C(O)R'°; or C(O)NR10R'°;
10 Each R is independently H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; Cl-ClO alkyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR°, NRBR13, COOR*3, NO2, CN, C(O)R' , C(O)NR R , NHC(O)R 3, or OC(O)R 3; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR13, N ' 3, COOR13, NO2, CN, C(O)R13, C(O)NRI3R13, NHC(O)R13, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with
1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-
C10 cycloalkenyl, halo, CF3, OR13, SR13, NR'Y3, COOR°, NO2, CN, C(O)R13,
C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
Each R15 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with 1-3 independent aryl, R or R groups; or Cl-ClO alkenyl substituted with 1-3
7 9 independent aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with 1-3
7 9 independent aryl, R or R groups; Cl-ClO alkenyl substituted with 1-3 independent aryl,
7 9 R or R ; or phenyl substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2- CIO alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R'2, NHC(O)R12, NH(COOR'2), S(O)2NR R , OC(O)R , Cl-ClO alkyl substituted with 1-3 independent R , halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R'2, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12;
19
Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group; and Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R9; halo; haloalkyl CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR'V2 S(O)2R12; N(Rl2)C(O)R12; N(R'2)(COOR12); N(R'2)S(O)2R'2; S(O)2NR12R12 OC(O)R12; NPV, 2C(O)NR12R12; NR'2C(O)C(O)R12; NR12C(O)R9; NRI 2S(O)2NR12R'2 NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R12, C(O)NRl 2R12, NHC(O)R12, NH(COOR12), S(O)2NR'2R12, OC(O)R12; or R12 . Preferred compounds include those of the formula above wherein X is O.
In another embodiment, the compounds of the formula above are those wherein,
R1 is H; COOR5; C(O)NR5R5; halo; C2-C10 alkyl; Cl-ClO alkenyl; Cl- CIO alkyl substituted with NR R , NR R , SR or OR ; or Cl-ClO alkenyl substituted with NR R , NR R , SR or OR ;
R2 is NR5R15; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl);
NR -NR5C(O)NR5R5; NR5-NR R16; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or C1-C10 alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
3 4 8 5
R is phenyl substituted with 1-3 independent R ; R ; COOR ; or Cl-ClO
7 8 alkyl substituted with aryl, R or R ; X is O or S;
4 Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl
CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5
OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R
NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R5 is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
9 or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 1 1 1 1 10 10 10 10 NR R , NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
NRV; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl; Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 1 1 1 1 I I halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; COOR*0; NO2; CN; C(O)R'°; or C(O)NRI0R10;
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-
C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR*3, NR' 3, COOR13, NO2,
CN, C(O)R13, C(O)NRl 3R13, NHC(O)R°, or OC(O)R13; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN,
C(O)R13, C(O)NRI3R13, NHC(O)R13, or OC(O)R13;
11 10 10 10
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C 1 -C 10 alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl, C3 -C 10 cycloalkyl, C4-
C10 cycloalkenyl, halo, CF3, OR13, SR13, NR'V3, COOR13, NO2, CN, C(O)R°,
C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
7 9 with one or two independent aryl, R or R groups; or C1-C10 alkenyl substituted with
7 9 aryl, R or R ; Each R1 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10
9 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
7 9 7 9 or two independent aryl, R or R groups; Cl -CIO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C 10 cycloalkyl, C4-C 10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR12, NO2, CN, C(O)R12, C(O)NR1 R12, NHC(O)R12, NH(COOR12), S(O)2NR'2R12, OC(O)R , Cl-ClO alkyl substituted with R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR'2R12, OC(O)R12;
19 Each R is independently H; C1 -CIO alkyl; C3-C 10 cycloalkyl or phenyl;
Each haloalkyl is independently a C1-C10 alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR'2R12 S(O)2R12; N(Rl2)C(O)R12; N(RI2)(COOR12); N(R'2)S(O)2R12; S(O)2NR*2R'2 OC(O)R12; NRl 2C(O)NR12R12; NR12C(O)C(O)R'2; NR'2C(O)R9; NR'2S(O)2NR12R'2 NR S(O)2R9; NR1 C(O)C(O)NR R ; C1-C10 alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R12, C(O)NR'V2, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R12 . Preferred compounds of this embodiment are also those wherein X is O. In another embodiment, the invention relates to a compound of the formula,
wherein,
R1 is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R16; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S;
4
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5 OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R" NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR$S(O)2R5; NR5S(O)2R* NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with 7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
„9 or R ;
Each R6 is independently C(O)R , COOR , or S(O)2 R5;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R , NR'V ', NR1 R11, COOR10, NO2, CN, C(O)R'°, or C(O)NR10R10 ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- CIO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 1 1 1 1 1 1 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
10 Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R13, C(O)NR,3R13, NHC(O)R13, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ; Each R12 is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with
1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-
C10 cycloalkenyl, halo, CF3, OR13, SR*3, NRBR13, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R°;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted
19 19 19 19 19 with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
14 Each R is each independently selected from Cl-ClO alkyl; C2-C10
8 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5 C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5 NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R* NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R15 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
7 9 7 9 or two independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R'2, OC(O)R , Cl-ClO alkyl substituted with R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; 17
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR$C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
19
Each R is independently H; C 1 -C 10 alkyl; C3-C 10 cycloalkyl or phenyl; Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl
12 12 12 12 12 12 12 12 12 CF3; OR ; SR ; NR R ; COOR ; NO2; CN; C(O)R ; C(O)C(O)R ; C(O)NR R
S(O)2R12; N(RI2)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR'V2
OC(O)R12; NR12C(O)NRI2R12; NR12C(O)C(O)R12; NR12QO)R9; NR12S(O)2NR12R'2
NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent
9 12 12 12 12 12 12 12 12
R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with
1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R ,
C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R*2 ;
4 17 14 wherein when all R and R are simultaneously H, R may not be Me, Cl, or OMe; and
14 17 wherein R and R may not simultaneously be Cl. Preferred compounds of this embodiment are also those wherein X is O. Alternatively, the compound has the formula
14 directly above wherein each R is independently selected from C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R8; I; Br; F; CF3; SR5; OR25; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; C1-C10 alkyl substituted with aryl, R7 or R8; or Cl-ClO alkenyl substituted with aryl, R7 or R8; and each R is independently H; C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R9; Cl-ClO alkyl substituted with one or two independent aryl, R7 or R9 groups; C3-C10 cycloalkyl substituted with one or two independent aryl, R7 or R9 groups; or Cl-ClO alkenyl substituted with aryl, R7 or R9;.
14
Alternatively, the compound has the formula directly above wherein each R is independently selected from NR5R5; NRV; NR C(O)NR R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR C(O)C(O)NR R ; or NR C(O)C(O)NR R . In alternate embodiments, the compound
4 17 is of any of the formulae above, wherein at least two of R and or R are independently H. Preferred compounds of these embodiments are also those wherein X is O. In an alternate embodiment, the inhibitory compound has the formula:
wherein, R is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR C(O)NR5R5; NR -NR R16; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S;
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl CF3; SR5; OR5; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5 OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ; Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R or R ; Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 11 1 1 1 1 10 10 10 10
NR R , NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; COOR10; NO2; CN; C(O)R10; or C(O)NR10R'°; Each R is independently H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; Cl-ClO alkyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R' , or OC(O)R°; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, ORB, SRB, NR' 3, COOR13, NO2, CN, C(O)R13, C(O)NRI3R13, NHC(O)R13, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ; Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR13, SRB, NR' 3, COOR13, NO2, CN, C(O)R°, C(O)NR13R13, NHC(O)R13, or OC(O)R13; Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
14
Each R is independently selected from Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8 R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ; Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
7 9 7 9 or two independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR12, NO2, CN, C(O)R12, C(O)NR,2R12, NHC(O)R12, NH(COOR12), S(O)2NR'2R12, OC(O)R , Cl-ClO alkyl substituted with R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R'2, OC(O)R12;
19 Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl;
CF3; OR12; SR12; NR*V2; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12;
S(O)2R12; N(R12)C(O)R12; N(Rl2)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12;
12 12 12 12 12 12 12 9 12 12 12
OC(O)R ; NR C(O)NR R ; NR C(O)C(O)R ; NR C(O)R ; NR S(O)2NR R ; NRl2S(O)2R9; NRI 2C(O)C(O)NR' R'2; Cl-ClO alkyl substituted with 1-3 independent
R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R12, C(O)NR12R12,
NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with
1-3 independent R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R12,
C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R12 ;
4 14 wherein when all R are H, R may not be Me or OMe. Preferred compounds of this embodiment are also those wherein X is O. Alternatively, the compound has the formula directly above wherein each R14 is independently selected from C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R8; halo; CF3; SR5; OR25; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl
7 8 7 8 substituted with aryl, R or R ; or Cl-ClO alkenyl substituted with aryl, R or R ; and each R25 is independently H; C2-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R9; Cl-ClO alkyl substituted with one or two
7 9 independent aryl, R or R groups; C3-C10 cycloalkyl substituted with one or two
7 9 7 9 independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R or R .
14
Alternatively, the compound has the formula directly above wherein each R is independently selected from NRV; NR5R6; NR5C(O)NRV; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NRV; NR5S(O)2R5; NR5S(O)2R8;
5 5 5 5 5 6
NR C(O)C(O)NR R ; or NR C(O)C(O)NR R . In alternate embodiments, the compound
4 is of any of the formulae above, wherein at least two of the R are independently H. Preferred compounds of these embodiments are also those wherein X is O.
In an alternate embodiment, the inhibitory compound has the formula,
wherein,
R is CN;
5 15 8 8
R is NR R ; OR ; R ; aryl; N(R )-N=CH(R ); N(R )-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R'6; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NRY, NRV, COOR5, NO2, CN, C(O)R5,
5 5 5 5 8
C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S; 4
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
8 C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl
CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5
OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5 NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8
NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 11 11 10 10 10 10 NR R , NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
NRV; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- CIO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; 10 10 10 10 10 11 1 1 1 1 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; COOR10; NO2; CN; C(O)R'°; or C(O)NR" V°;
10
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R13, C(O)NRI3R13, NHC(O)R!3, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ; Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- CIO cycloalkenyl, halo, CF3, OR13, SR13, NR13R13, COOR13, NO2, CN, C(O)R13, C(O)NR,3R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR19, SR19, NR'9R 9, COOR , NO2, CN;
14
Each R is independently selected from C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; C1-C10 alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted 7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10
9 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
17
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5 C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5 NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8 NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
19
Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl; Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl;
CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12;
12 12 12 12 12 12 12 12 12
S(O)2R ; N(R )C(O)R ; N(R )(COOR ); N(R )S(O)2R ; S(O)2NR R ;
OC(O)R12; NR12C(O)NRI2R12; NR12C(O)C(O)R12; NR12C(O)R9; NRI2S(O)2NR12R12;
NR* S(O)2R9; NR C(O)C(O)NR' R12; Cl-ClO alkyl substituted with 1-3 independent
9 12 12 12 12 12 12 12 12 R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R*2, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R'2 ; wherein R14 and R17 may not simultaneously be Cl. Preferred compounds of this embodiment are also those wherein X is O. Alternatively, the compound has the formula directly above wherein each R17 is independently selected from from H, Cl-ClO alkyl C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R8; I; Br; F; CF3; SR5; OR5; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R C(O)NR5R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R! NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; Cl-ClO alkyl substituted with aryl, R7 or R8; or Cl-ClO alkenyl substituted with aryl, R7 or R8.
14
Alternatively, the compound has the formula directly above wherein each R is independently selected from NR R ; NR R ; NR C(O)NR R5; NR C(O)C(O)R ;
NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR C(O)C(O)NR R ; or NR C(O)C(O)NR R . In alternate embodiments, the compound
4 17 is of any of the formulae above, wherein at least two of R and or R are independently H. Preferred compounds of these embodiments are also those wherein X is O. In another embodiment, the inhibitory compound has the formula,
wherein ,
R is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl);
NR -NR C(O)NR R ; NR -NR R ; NR -NR R ; Cl-ClO alkyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5,
C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3,
SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or
S(O)2NR5R5;
3 8 5 7 8
R is R ; COOR ; or Cl-ClO alkyl substituted with R , R , or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, R9, halo, CF3, OR12, SR12, NRI 2R12, COOR*2, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NRl 2R12, OC(O)R12, Cl-ClO alkyl substituted with R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR, 2R'2,
12 3
OC(O)R ; wherein R is not unsubstituted furanyl, unsubstituted thienyl or unsubstituted pyridyl; X is O or S;
4
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5 OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R" NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 1 1 1 1 10 10 10 10 NR R , NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl; 9
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR°, SR13, NR' 3, COOR13, NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR13, NR' 3, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)RB;
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-
C10 cycloalkenyl, halo, CF3, OR13, SR°, NR°R13, COOR13, NO2, CN, C(O)RB,
C(O)NRΥ3, NHC(O)R13, or OC(O)RB;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally
19 19 19 19 19 substituted with halo, CF3, OR , SR , R R , COOR , NO2, CN;
Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
7 9 with one or two independent aryl, R or R groups; or C1-C10 alkenyl substituted with
7 9 aryl, R or R ; Each R1 is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10
9 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one or two
7 9 7 9 independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR'2), S(O)2NR12R'2, OC(O)R12, Cl-ClO alkyl substituted with R9, halo, CF3, OR*2, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR'2R12, OC(O)R12;
19 Each R is independently H; Cl -CIO alkyl; C3-C 10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl CF3; OR*2; SR12; NR' 2; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12 S(O)2R12; N(R12)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR12Ri 2 OC(O)R12; NRl2C(O)NR12R12; NRl C(O)C(O)R12; NR'2C(O)R9; NR' S(O)2NR'2R12 NR S(O)2R ; NR C(O)C(O)NR R ; C1-C10 alkyl substituted with 1-3 independent
9 12 12 12 12 12 12 12 12
R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with
1-3 independent R , halo, CF3, OR1 , SR1 , NR R , COOR , NO2, CN, C(O)R ,
12 12 12 12 12 12 12 12
C(O)NR R , NHC(O)R , NH(COOR ), S(O)2NR R , OC(O)R ; or R
3 8 Alternatively, the compound has the formula directly above wherein each R is R , and
3 8 8 alternatively, wherein R is R that is attached by a nitrogen atom in the R ring system. Preferred compounds of these embodiments are also those wherein X is O. In another embodiment, the inhibitory compound has the formula,
wherein,
R2 is NR5R5; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R15; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5; X is O or S;
4 R is one, two, or three substituents, each independently selected from H,
Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R8; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2 CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5 NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8 NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5
NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with aryl, R? or R ; or Cl-ClO alkenyl
7 8 substituted with aryl, R or R ;
Each R5 is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
__ 9 or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ; 7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 1 1 11 10 10 10 10
NR R , NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NRV; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl-
C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 1 1 1 1 1 1 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ; Each R10 is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR*3, SR13, NR' 3, COOR13, NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- WO 00/43373 PCTVUSOO/01581
CIO cycloalkenyl, halo, CF3, OR*3, SR13, NR' 3, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)RB;
Each R1 is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted
19 19 19 19 19 with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
18 18
Each R is independently Cl-ClO alkyl or both R may be taken together
18 as a C2-C7 alkyl chain; wherein any R may optionally be substituted with 1-3
7 8 independent R or R ;
19 Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl;
CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R'2;
S(O)2R12; N(R12)C(O)R12; N(RI2)(COOR12); N(R12)S(O)2R12; S(O)2NR'2R'2;
12 12 12 12 12 12 12 9 12 12 12
OC(O)R ; NR C(O)NR R ; NR C(O)C(O)R ; NR C(O)R ; NR S(O)2NR R ; NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R12, C(O)NR'2R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R ,
C(O)NRI2R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R12 . Preferred compounds of this embodiment are also those wherein X is O.
The invention also relates to methods of inhibiting enzyme or polypeptide activity, particularly of an enzyme or polypeptide described herein, such as a kinase, in a mammal comprising the step of administering to said mammal a compound of any of the formulae described herein or a composition comprising a compound of any of the formulae described herein. In one embodiment, the invention relates to a method of inhibiting kinase activity in a mammal comprising the step of administering to said mammal a compound, or a composition comprising a compound, of any one of the formulae described herein. Preferably, the mammal is a human.
In another embodiment, the invention relates to a method of inhibiting enzyme activity in a mammal comprising the step of administering to said mammal a compound, or a composition comprising a compound, of any of the formulae described herein. Preferably, the mammal is a human.
The invention also relates to methods of treating disease and/or disease symptoms, particularly those mediated by an enzyme or polypeptide described herein, such as kinase mediated disease or disease symptoms, in a mammal comprising the step of administering to said mammal a compound of any of the formulae described herein or a composition comprising a compound of any of the formulae described herein. Such diseases or disease symptoms are described herein. "Kinase mediated" disease or disease symptoms refers to disease or disease symptoms in which kinase activity is involved. In one embodiment, this invention relates to a method of treating disease or disease symptoms, particularly kinase mediated disease or disease symptoms, in a mammal comprising the step of administering to said mammal a compound, or a composition comprising a compound, of any of the formulae described herein. Preferably, the mammal is a human.
In an alternate embodiment, this invention relates to a method of treating disease or disease symptoms in a mammal comprising the step of administering to said mammal a compound, or a composition comprising a compound, of any of the formulae described herein. Preferably, the mammal is a human.
In the compounds described herein, the term "halo" refers to any radical of fluorine, chlorine, bromine or iodine. The terms "alkyl", "alkenyl" and "alkynyl" refer to hydrocarbon chains that may be straight-chain or branched-chain, containing the indicated number of carbon atoms. For example, Cl-ClO indicates the group may have from 1 to 10 (inclusive) carbon atoms in it. The terms "ring" and "ring system" refer to a ring comprising the delineated number of atoms, said atoms being carbon or, where indicated, a heteroatom such as nitrogen, oxygen or sulfur. The ring itself, as well as any substitutents thereon, may be attached at any atom that allows a stable compound to be formed.
In the methods described herein, said mammal is preferably a human. The inhibitors described herein, however, are useful in inhibiting kinase activity in human cells and useful in murine and other species used as surrogates for investigating activity in vitro and in vivo in humans and against human kinases. The inhibitors described herein are also useful for investigating inhibition and activity of kinases originating from species other than humans.
The compounds and compositions described herein are useful for inhibition of kinase activity of one or more enzymes. Kinases include, for example, protein kinases, lipid kinases (e.g., phosphatidylinositol kinases PI-3, PI-4) and carbohydrate kinases. Further information relating to kinase structure, function and and their role in disease or disease symptoms is available at the Protein Kinase Resource web site (http : //www . sdsc . edu/Kinases/pk home . tml ) . Kinases may be of prokaryotic, eukaryotic, bacterial, viral, fungal or archaea origin. Specifically, the compounds described herein are useful as inhibitors of tyrosine, serine/threonine or histidine protein kinases. Examples of kinases that are inhibited by the compounds and compositions described herein and against which the methods described herein are useful include, but are not limited to, LCK, IRK (= INSR = Insulin receptor), IGF-1 receptor, SYK, ZAP-70, IRAKI, IRAK2, BLK, BMX, BTK, FRK, FGR, FYN, HCK, ITK, LYN, TEC, TXK, YES, ABL, SRC, EGF-R (= ErbB-1), ErbB-2 (= NEU = HER2), ErbB-3, ErbB-4, FAK, FGF1R (= FGR-1), FGF2R (= FGR-2), IKK-1 (= IKK-ALPHA = CHUK), IKK-2 (= IKK-BETA), MET (= c-MET), NIK, PDGF receptor ALPHA, PDGF receptor BETA, TIE1, TIE2 (= TEK), VEGFR1 (= FLT-1), VEGFR2 (= KDR), FLT-3, FLT-4, KIT, CSK, JAK1, JAK2, JAK3, TYK2, RIP, RIP-2, LOK, TAK1, RET, ALK, MLK3, COT, TRKA, PYK2, EPHB4, RON, GSK3, UL13, ORF47, ATM, CDK (including all subtypes), PKA, PKB (including all PKB subtypes) (=AKT-1, AKT-2, AKT-3), PKC (including all PKC subtypes), and bARKl (=GRK2) (and other G-protein coupled receptor kinases (GRKs)), and all subtypes of these kinases. The compounds and compositions of the invention are therefore also particularly suited for treatment of diseases and disease symptoms that involve one or more of the aforementioned protein kinases. In one embodiment, the compounds, compositions or methods of this invention are particularly suited for inhibition of or treatment of disease or disease symptoms mediated by LCK, ZAP, LYN, EGFR, ERB-B2, KDR, ITK, BTK, or SYK. In another embodiment, the compounds, compositions or methods of this invention are particularly suited for inhibition of or treatment of disease or disease symptoms mediated by src-family kinases. In another embodiment, the compounds, compositions or methods of this invention are particularly suited for inhibition of or treatment of disease or disease symptoms mediated by kinases in one of the kinase families defined by Hardie & Hanks, ed. supra. The compounds and compositions are also suited for regulating or modulating signal transduction in signal transduction pathways that involve one or more kinases, thus affecting events in a cell, and are therefor useful in methods for regulating or modulating signal transduction.
The inhibitors described herein are also useful for inhibiting the biological activity of any enzyme comprising greater than 90%, alternatively greater than 85%, or alternatively greater than 70% sequence homology with a kinase sequence, including the kinases mentioned herein. The inhibitors described herein are also useful for inhibiting the biological activity of any enzyme comprising a subsequence, or variant thereof, of any enzyme that comprises greater than 90%, alternatively greater than 85%, or alternatively greater than 70% sequence homology with a kinase subsequence, including subsequences of the kinases mentioned herein. Such subsequence preferably comprises greater than 90%, alternatively greater than 85%, or alternatively greater than 70% sequence homology with the sequence of an active site or subdomain of a kinase enzyme. The subsequences, or variants thereof, comprise at least about 300, or alternatively at least about 200, amino acids. The inhibitors described herein are useful for inhibiting the biological activity of any enzyme that binds ATP and thus for treating disease or disease symptoms mediated by any enzyme that binds ATP. The inhibitors described herein are also useful for inhibiting the biological activity of any enzyme that is involved in phosphofransfer and thus for treating disease or disease symptoms mediated by any enzyme that is involved in phosphotransfer. The inhibitors described herein are also useful for inhibiting the biological activity of a polypeptide or enzyme having sequence homology with a kinase sequence and thus for treating disease or disease symptoms mediated by such polypeptide or enzyme. Such polypeptides or enzymes may be identified by comparison of their sequence with kinase sequences and kinase catalytic domain sequences. For example, one method of comparison involves the database PROSITE (http://expasy.hcuge.ch), containing "signatures" or sequence patterns (or motifs) or profiles of protein families or domains. Thus, the inhibitors described herein are useful for inhibiting the biological activity of a polypeptide or enzyme comprising a sequence that comprises a "signature" or sequence pattern or profile derived for, and identified in PROSITE as relating to kinases, and for treating disease or disease symptoms mediated by such polypeptide or enzyme. Examples of such PROSITE motifs or consensus patterns identified as relating to kinases include PS00107, PS00108, PS00109, PS50011, PS00915, and PS00916.
The compounds, compositions and methods described herein are useful in inhibiting kinase activity. As such, the compounds, compositions and methods of this invention are useful in treating kinase-mediated disease or disease symptoms in a mammal, particularly a human. Kinase mediated diseases are those wherein a protein kinase is involved in signaling, mediation, modulation, or regulation of the disease process. Kinase mediated diseases are exemplified by the following disease classes: cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, angiogenesis, neovascularization, vasculogenesis, cardiovascular, and the like.
The compounds, compositions and methods described herein are useful in treating or preventing diseases or their symptoms, including, transplant rejection (e.g., kidney, liver, heart, lung, pancreas (islet cells), bone marrow, cornea, small bowel, skin allografts or xenografts), graft versus host disease, osteoarthritis, rheumatoid arthritis, multiple sclerosis, diabetes, diabetic retinopathy, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitis), renal disease, cachexia, septic shock, lupus, diabetes mellitus, myasthenia gravis, psoriasis, dermatitis, eczema, seborrhea, Alzheimer's disease, Parkinson's disease, stem cell protection during chemotherapy, ex vivo selection or ex vivo purging for autologous or allogeneic bone marrow transplantation, leukemia (acute myeloid, chronic myeloid, acute lymphoblastic, etc.), cancer (breast, lung, colorectal, ovary, prostate, renal, squamous cell, prostate, glioblastoma, melanoma, pancreatic, Kaposi's sarcoma, etc.), occular disease, retinopathies, (e.g., macular degeneration, diabetic retinopathy), corneal disease, glaucoma, bacterial infections, viral infections, fungal infections and heart disease, including but not limited to, restenosis. In one embodiment, the compositions and methods described herein are useful in treating or preventing rheumatoid arthritis, transplant rejection, asthma or allergy, or their symptoms. Another embodiment envisioned by this invention relates to the use of the kinase inhibitory compounds described herein for use as reagents that effectively bind to kinases. As reagents, the compounds of this invention, and their derivatives, may be derivatized to bind to a stable resin as a tethered substrate for affinity chromatography applications. The compounds of this invention, and their derivatives, may also be modified (e.g., radiolabelled or affinity labelled, etc.) in order to utilize them in the investigation of enzyme or polypeptide characterization, structure, and/or function. These and other uses that characterize kinase inhibitors will be evident to those of ordinary skill in the art.
In another embodiment, the inhibitors described herein are useful for crystallizing or co-crystallizing with a protein kinase. Such crystals or crystal complexes may additionally comprise additional peptides and or metal ions. The crystals or crystal complexes may be used for investigation and determination of enzyme characteristics including, for example, structure of the kinase enzyme, enzyme active site domains, and inhibitor-enzyme interactions. This information is useful in developing inhibitor compounds with modified characteristics and for understanding structure-function relationships of the enzymes and their enzyme-inhibitor interactions.
In an alternate embodiment, the inhibitory compounds described herein may be used as platforms or scaffolds which may be utilized in combinatorial chemistry techniques for preparation of derivatives and/or chemical libraries of compounds. Such derivatives and libraries of compounds have kinase inhibitory activity and are useful for identifying and designing compounds possessing kinase inhibitory activity. Combinatorial techniques suitable for utilizing the compounds described herein are known in the art as exemplified by Obrecht, D. and Villalgrodo, J.M., Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998), and include those such as the "split and pool" or "parallel" synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, A.W., Curr. Opin. Chem. Bio., (1997) 1, 60. Thus, one embodiment relates to a method of using the compounds described in the formulae herein for generating derivatives or chemical libraries comprising: 1) providing a body comprising a plurality of wells; 2) providing one or more compounds of the formulae described herein in each well; 3) providing an additional one or more chemicals in each well; 4) isolating the resulting one or more products from each well. An alternate embodiment relates to a method of using the compounds described in the formulae herein for generating derivatives or chemical libraries comprising: 1) providing one or more compounds of the formulae described herein attached to a solid support; 2) treating the one or more compounds of the formulae described herein attached to a solid support with one or more additional chemicals; 3) isolating the resulting one or more products from the solid support. In the methods described above, "tags" or identifier or labeling moieties may be attached to and/or detached from the compounds of the formulae herein or their derivatives, to facilitate tracking, identification or isolation of the desired products or their intermediates. Such moieties are known in the art. The chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. Examples of such chemicals are those that appear in the various synthetic and protecting group chemistry texts and treatises referenced herein.
The compounds of the formulae herein may be used to study the mechanism and role of proteins in biological pathways and processes involving kinases. The compounds of the formulae herein may also be used as probes to identify new kinase enzymes or polypeptides with sequence homology to kinases. The inhibitor compounds may be tethered to a support or modified (e.g., tagged, radiolabeled or other identifiable detection method) such that the compound may be detected and isolated in the presence of the kinase enzyme or polypeptide. Thus, another embodiment relates to a method of identifying and/or isolating a kinase enzyme or polypeptide with sequence homology to a kinase enzyme sequence or subsequence, comprising, contacting a tethered or modified compound of any of the formulae herein with one or more polypeptides, isolating a polypeptide/inhibitor complex, and identifying or isolating the sequence of the polypeptide in the polypeptide/inhibitor complex. The identification of the polypeptide sequence may be performed while in the polypeptide/inhibitor complex or after the polypeptide is decomplexed from the tethered or modified compound of any of the formulae herein.
Table 1 lists representative individual compounds of the invention and compounds employed in the compositions and methods of this invention.
Table 1 2
23 24
113 114
115 116
117 118
119 120
123 124
125 126
127 128
133 134
1
147 148
153 154
157 158
159
177 178
189 190
193 194
195 196
199 200
201 202
203 204
213 214
219 220
225 226
229 230
235 236
237
239 240
249 250
255 256
257
259 260
263 264
265 266
267 268
269 270
271 272
273 274
275 276
277 278
279 280
281 282
283 284
285 286
287 288
289 290
291 292
293 294
295 296
297 298
299 300
301 302
303 304
305 306
307 308
309 310
311 312
317 318
Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a mammal or for use in affinity chromatography applications). Typically, such compounds are stable at a temperature of 40 °C or less, in the absence of excessive moisture for at least one week. As used herein, the compounds of this invention, including the compounds of formulae described herein, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g.,
+ magnesium), ammonium and N-(alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
The compounds of this invention may be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials. In general, the compounds of the formulae described herein are conveniently obtained via methods illustrated in General Synthetic Schemes I-IV and the Examples herein. These general schemes are also exemplified by the specific methods described in the Examples section below.
Thus, one embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulae described herein. Another embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the examples herein and then converting that intermediate(s) to a compound of the formulae described herein. Another embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulae described herein utilizing one or more of the chemical reactions described in the synthetic schemes or examples herein.
Nucleophilic agents are known in the art and are described in the chemical texts and treatises referred to herein. The chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. The methods described above may also additionally comprise steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compound of the formulae described herein. General Synthetic Scheme I
RNH,
General Synthetic Scheme II
Where X = N, O, S; P = suitable protecting group and R' = alkyl or acyl General Synthetic Scheme III
General Synthetic Scheme IV
In General Synthetic Scheme I, an appropriate benzaldehyde (SI) is converted to pyrimidinone S2 by reaction with an appropriate cyanoacetate (or equivalent) S- methylisothiouronium sulphate. Pyrimidinone S2 may be reacted with a substituted aniline or amine to form pyrimidinone S3. In a similar fashion, as illustrated in General Synthetic Scheme π, a protected benzaldehyde (S4) may be reacted under the same conditions to provide pyrimidinone S5. Pyrimidinone S5 can be subsequently reacted with an aniline, amine or other appropriate heteroatom nucleophile to provide pyrimidinone S6. Subsequent deprotection (S7) and functionalization of the resultant heteroatom provides S8. Alternatively, as shown in General Synthetic Scheme III, an appropriately substituted β-ketoester (S9) can be condensed under similar conditions with S- methylisothiouronium sulphate to afford pyrimidinone SIO. Nucleophilic addition to SIO then provides SI 1. Additionally, as illustrated in General Synthetic Scheme IV, an appropriately substituted β -ketoester (S9) can be condensed with thiourea to afford S12. Subsequent sulfur alkylation and nucleophilic addition provides pryimidinone S13.
Thus, one embodiment relates to a method of making a compound of the formulae described herein, comprising 1) the step of reacting an aldehyde (or equivalent) with a cyanoacetate (or equivalent) and an alkylisothiouronium salt to form a pyrimidinone; 2) reacting said pyrimidinone with a nucleophilic agent (e.g., an aniline or amine) to form the compound of the formulae described herein. Nucleophilic agents are known in the art and are described in the chemical texts and treatises referred to herein. Such agents may have carbon or a heteroatom (e.g, N, O, S) as the nucleophilic atom. In an alternate embodiment, the method of making a compound of the formulae described herein, comprises 1) preparation of a thio-substituted pyrimidone intermediate (as exemplified by S2, S5, SIO and S12 in the General Synthetic Schemes); and 2) reacting the pyrimidinone of step 1 with another chemical to form the compound of the formulae described herein.
The chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. The methods described above may also additionally comprise steps, either before or after steps 1 and 2 described above, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compound of the formulae described herein.
As can be appreciated by the skilled artisan, the above synthetic schemes are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the inhibitor compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995).
The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
The novel compounds of the present invention are excellent ligands for protein kinases, subsequences thereof, and homologous polypeptides. Accordingly, these compounds are capable of targeting and inhibiting kinase enzyme and subsequences thereof. Inhibition can be measured by various methods, including, for example, those methods illustrated in the examples below. The compounds described herein may be used in assays, including radiolabelled, antibody detection and fluorometric, for the isolation, identification, or structural or functional characterization of enzymes, peptides or polypeptides. Such assays include any assay wherein a nucleoside or nucleotide are cofactors or substrates of the peptide of interest, and particularly any assay involving phosphofransfer in which the substrates and or cofactors are ATP, GTP, Mg, Mn, peptides or polymeric amino acids. Pharmaceutical compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; an additional agent selected from an immunosuppressant, an anticancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyperproliferation compound; and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternate compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle. Such compositions may optionally comprise additional therapeutic agents, including, for example, immunosuppressants, anti-cancer agents, anti-viral agents, antiinflammatory agents, antifungal agents, antibiotics, or anti-vascular hyperproliferation compounds.
The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3- butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically- transdermal patches are also included in this invention.
The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absoφtion promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, alternatively between about 0.5 and about 75 mg kg body weight per day of the kinase inhibitory compounds described herein are useful in a monotherapy and/or in combination therapy for the prevention and treatment of kinase mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound. When the compositions of this invention comprise a combination of a kinase inhibitor of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the kinase inhibitor and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
According to one embodiment, the pharmaceutical compositions of this invention comprise an additional immunosuppression agent. Examples of additional immunosuppression agents include, but are not limited to, cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin, prednisone, azathioprine, mycophenolate mofetil, OKT3, ATAG, interferon and mizoribine.
According to an alternate embodiment, the pharmaceutical compositions of this invention may additionally comprise cytotoxic or hormonal anti-cancer agents or combinations thereof. Examples of anti-cancer agents include, but are not limited to, cis- platin, actinomycin D, doxorubicin, vincristine, vinblastine, etoposide, amsacrine, mitoxantrone, tenipaside, taxol, taxotere, colchicine, cyclosporin A, phenothiazines, interferons, thioxantheres, anti-estrogens (e.g., tamoxifen), aromatase inhibitors, anti- androgens, and LHRH antagonists. According to another alternate embodiment, the pharmaceutical compositions of this invention may additionally comprise an anti-viral agent. Examples of anti-viral agents include, but are not limited to, Cytovene, Ganciclovir, trisodium phosphonoformate, Ribavirin, d4T, ddl, AZT, amprenavir and acyclovir.
Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician. In an alternate embodiment, this invention provides methods of treating, preventing, or relieving symptoms of disease in a mammal comprising the step of administrating to said mammal any of the pharmaceutical compositions and combinations described above. Preferably, the mammal is a human. If the pharmaceutical composition only comprises the inhibitor of this invention as the active component, such methods may additionally comprise the step of administering to said mammal an additional therapeutic agent, such as an antiinflammatory agent, immunosuppressant, an anti-cancer agent, an anti-viral agent, or an anti-vascular hypeφroliferation compound. Such additional agent may be administered to the mammal prior to, concurrently with, or following the administration of the inhibitor composition. The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention. The compounds of this invention may also be represented in multiple tautomeric forms, for example, as illustrated below:
in such instances, the invention expressly includes all tautomeric forms of the compounds described herein. The compounds may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
Substituents on ring moieties (e.g., phenyl, thienyl, etc.) may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom (see below), whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen). For example, a structure drawn as:
is intended to encompass all of the following structures:
All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incoφorated by reference in their entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.
In order that the invention described herein may be more readily understood, the following examples are set forth. It should be understood that these examples are for illustrative puφoses only and are not to be construed as limiting this invention in any manner. NMR and MS spectra obtained for compounds described in the examples below and those described herein were consistent with that of the compounds of the formulae herein. Example 1
COzEt
To a mixture of 1.39g (5 mmol) S-methylisothiouronium sulphate and 1.36g (1.22mL; 10 mmol) in 50 mL of dry pyridine is added 1.13g (1.06 mL; 10 mmol) of ethylcyano acetate and 5 g (61 mmol) of anhydrous sodium acetate. The mixture is refluxed (135°C) under calcium carbonate for 4 hours. The resultant mixture is cooled and filtered under vacuum and the filtrate evaporated under high-vac. The solid product is suspended in glacial acetic acid and the resulting suspension was evaporated under high-vac. The solid is then suspended in dichloromethane, filtered, and is washed with excess dichloromethane to provide product of purity sufficient for subsequent manipulations.
Example 2
A mixture of 25 mg (.09 mmol) of the product from Example 1 and 200 mg of p- chloroaniline is heated by heat gun until a homogeneous solution is obtained. The reaction is heated at 170°C until such time as the solution solidifies. The product is broken up and suspended in dichloromethane and filtered while washing with excess dichloromethane.
Example 3
To a solution of 360 mg (1.6 mmol) of ketoester in 5 mL of anhydrous pyridine is added 451 mg (1.6 mmol) of S-methylisothiouronium sulphate and 1.33 g (16.2 mmol) of anhydrous sodium acetate. The mixture is refluxed (135°C) under calcium carbonate for 7 hours. The resultant mixture is cooled and filtered under vacuum and the filtrate evaporated under high-vac. The solid product is suspended in glacial acetic acid and the resulting suspension is evaporated under high-vac. The solid is then re-suspended in diethylether, filtered, and washed with excess diethylether to provide product of purity sufficient for subsequent manipulations. Example 4
A dry two-necked flask fitted with reflux condenser is charged, under argon, with 126 mg (5.5 mmol) sodium metal and 3 mL absolute ethanol. The sodium is dissolved with mild heating over about one hour. To this solution is added 292 mg (3.8 mmol) of thiourea. After brief stirring, 646 mg (2.7 mmol) ketoester in one mL absolute ethanol is added followed by an additional one mL of absolute ethanol containing residual ketoester from the transfer vessel. The solution is refluxed for five hours at which time it is cooled and evaporated to dryness. The residue is taken up in water, neutralized with glacial acetic acid, and extracted into ethyl acetate (2 X 25mL). The organic layer is separated, dried over magnesium sulfate, filtered, and evaporated under vacuum. The residue is recrystallized from ethanol to yield pure product.
Example 5
To a solution of 161 mg (0.65 mmol) of pyrimidinone in 5 mL of DMF is added 90 mg (0.65 mmol) pulverized potassium carbonate and 44 μL (0.70 mmol) of methyl iodide. The suspension is stirred under argon for one hour at which point it is added to water (5 mL). The water is extracted with ethyl acetate (2 X 25 mL) and the organic layer is dried over magnesium sulfate, filtered and evaporated under vacuum. The resulting residue is of sufficient purity to be utilized directly in subsequent reactions. Example 6
To a solution of 39 mg (0.12 mmol) pyrimidinone in 1 mL of DMF is added 21 mg (0.12 mmol) N-bromosuccinimide. After stirring for 5 minutes, the reaction is quenched with a few drops of saturated aqueous sodium bisulfite. The solution is then diluted with ethyl acetate and the resulting precipitate is filtered to provide pure bromide. The ethyl acetate is washed with water (2 X 2 mL), dried over magnesium sulfate, filtered, and evaporated under vacuum to provide additional crude product.
Example 7
The inhibitor compounds described herein are screened in the following manner. Kinases suitable for use in the following protocol to determine kinase activity of the compounds described herein include, but are not limited to: Lck, Lyn, Src, Fyn, Syk, Zap- 70, Itk, Tec, Btk, EGFR, ErbB2, Kdr, Flt-1, Flt-3, Tek, c-Met, InsR.
Kinases are expressed as either kinase domains or full length constructs fused to glutathione S-transferase (GST) or polyHistidine tagged fusion proteins in either E. coli or Baculovirus-High Five expression systems. They are purified to near homogeneity by affinity chromatography essentially as previously described (Lehr et al., 1996; Gish et al., 1995). In some instances, kinases are co-expressed or mixed with purified or partially purified regulatory polypeptides prior to measurement of activity.
Kinase activity and inhibition are measured essentially by established protocols (Braunwalder et al., 1996). Briefly, The transfer of 33PO4 from ATP to the synthetic substrates poly(Glu, Tyr) 4:1 or poly(Arg, Ser) 3:1 attached to the bioactive surface of microtiter plates serves as the basis to evaluate enzyme activity. After an incubation period, the amount of phosphate transferred is measured by first washing the plate with 0.5% phosphoric acid, adding liquid scintillant, and then counting in a liquid scintillation detector. The IC50 is determined by the concentration of compound that causes a 50% reduction in the amount of 33P incoφorated onto the substrate bound to the plate.
Other similar methods whereby phosphate is transferred to peptide or polypeptide substrate containing tyrosine, serine, threonine, or histidine, either alone, in combination, or in combination with other amino acids, in solution or immobilized (i.e., solid phase) are also useful. Alternatively, kinase activity can be measured using antibody-based methods whereby an antibody or polypeptide is used as a reagent to detect phosphorylated target polypeptide. The compounds of the invention described herein are potent and selective kinase inhibitors as demonstrated by representative compounds described herein that inhibit one or more kinases with ICso values at less than about 5 μM or greater, at less than about 1 μM, or at less than about 300 nM.
References: Braunwalder AF, Yarwood DR, Hall T, Missbach M, Lipson KE, Sills MA. (1996). A solid-phase assay for the determination of protein tyrosine kinase activity of c-src using scintillating microtitration plates. Anal Biochem. 234(l):23-26.
Gish G, McGlone ML, Pawson T, Adams JA. (1995). Bacterial expression, purification and preliminary kinetic description of the kinase domain of v-fps. Protein Eng. 8(6):609- 614.
Lehr RV, Ma YG, Kratz D, Brake PG, Wang S, Faltynek CR, Wang XM, Stevis PE (1996). Production, purification and characterization of non-myristylated human T-cell protein tyrosine kinase in a baculovirus expression system. Gene 169(2):27527-9.
Example 8
The cellular activities of the inhibitor compounds described herein may be assessed in a number of assays known to those skilled in the art, some of which are exemplified as described below. Typical sources for cells include, but are not limited to, human bone marrow or peripheral blood lymphocytes, or their equivalents, or rodent spleen cells. Transformed cell lines that have been reported as cytokine- and growth factor-dependent cells are available from standard cell banks such as The American Type Culture Collection (Bethesda, MD). Cells genetically manipulated to express a particular kinase or kinases are also suitable for use in assaying cellular activity. These cells are grown in various standard tissue culture media available from suppliers such as GIBCO/BRL (Grand Island, NY) supplemented with fetal bovine serum. Cellular activity may also be measured using bacterial, yeast, or virally infected mammalian cells. Standard inhibitors of cell activation include mycophenolic acid (SIGMA, St. Louis, MO), staurosporine (Calbiochem, San Diego, CA), wortmannin (Calbiochem), cyclosporine, FK-506, and steroids (e.g., corticosteroids).
The compound(s) are tested for activity in cellular assays of T or B cell activation. For example, the receptor-induced production of cytokines and/or cell proliferation is a useful measure. This assay is performed similarly to techniques described in the literature (1,2), and involves antibody-, antigen-, mitogen-, or antigen presenting cell-mediated crosslinking of the T cell or B cell receptor with or without engagement of co-stimulatory receptors.
The compound(s) are tested for activity in cellular assays of allergic mediator release. For example, the receptor-induced degranulation in mast cells or basophils leading to histamine release and the production of cytokines is a useful measure. This assay is performed similarly to techniques described in the literature (3), and involves crosslinking of antigen-specific IgE on cells leading to degranulation and or cytokine production.
The compound(s) are tested for activity in cellular assays of growth factor effects. For example, growth factor receptor-induced signaling in a cell leading to intracellular signaling events such as kinase autophosphorylation, phosphorylation of relevant kinase substrates, phosphorylation of MAP kinases, or induction of gene expression. Also, for example, growth factor-induced functional events in cells such as DNA synthesis, proliferation, migration, or apoptosis. These assays are performed similarly to techniques described in the literature (4-7), and involve addition of growth factor to responsive cells followed by monitoring of signaling or functional events.
The compound(s) are tested for activity in cellular assays of cytokine activation. For example, cytokine-induced intracellular signaling events and/or cell proliferation and/or cytokine production are a useful measure. This assay is performed similarly to techniques described in the literature (8), and involves addition of cytokine to responsive cells followed by monitoring intracellular signaling events and/or cell proliferation and/or cytokine production.
References: 1. Shuji, K., et al. Activation of p21-CDC42/Rac-activated kinases by CD28 signaling: p21 -activated kinase (PAK) and MEK kinase 1 (MEKK1) may mediate the inteφlay between CD3 and CD28 signals. J. Immunol. 160: 4182-4189 (1998).
2. Satterthwaite, A.B., et al., Independent and opposing roles for Btk and Lyn in B cell and myeloid signaling pathways. J. Exp. Med. jj?8: 833-844 (1998).
3. Stephan, N., et al. FcεRl -induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells (RBL-2H3). J Biol. Chem. 267 (8): 5434-5441 (1992).
4. Olayioye, M.A., et al. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Molecular and Cellular Biology. 18(9): 5042-5051 (1998). 5. Buchdunger, E., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56;101-104 (1996).
6. Yoshida, A. et al., Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 13:57-64 (1996).
7. Brunet, A., et al., Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 96:857-868 (1999). 8. Liu, K.D., et al. Janus kinases in interleukin-2-mediated signaling: JAK1 and
JAK3 are differentially regulated by tyrosine phosphorylation. Current Biology. 7 (11): 817-826 (1997).
While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the products and processes of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims rather than by the specific embodiments that have been represented by way of example.

Claims

Claims What is claimed is:
1. A compound of the formula:
wherein ,
R1 is H; CN; COOR5; C(O)NR5R5; halo; Cl-ClO alkyl; Cl-ClO alkenyl; Cl-ClO alkyl substituted with 1-3 independent NR R , NR R , SR or OR ; or Cl-ClO
5 5 5 6 5 5 alkenyl substituted with 1-3 independent NR R , NR R , SR or OR ;
R2 is NR5R5; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R15; NR5-NR5R6; Cl-ClO alkyl substituted with 1-3 independent aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R , C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with 1-3 independent aryl, R , halo, CF3, SR , OR , OC(O)R , NR R , NR R , COOR , NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
3 4 8 5
R is phenyl substituted with 1-3 independent R ; R ; COOR ; or Cl-ClO
7 8 alkyl substituted with 1-3 independent aryl, R or R ; X is O or S;
4
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5 OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5 NR5(COOR5); NR?C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8 NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10
9 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with 1-3 independent aryl, R or R groups; C3-C10 cycloalkyl substituted with 1-3
7 9 independent aryl, R or R groups; or Cl-ClO alkenyl substituted with 1-3 independent
7 9 aryl, R or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 1 1 11 10 10 10 10
NR R , NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R9; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with 1-3
7 9 7 9 independent R , R or aryl; or C1-C10 alkenyl substituted with 1-3 independent R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
Each R1 is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- CIO cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR°, SR13, NR' 3, COOR13, NO2,
CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN,
C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
11 10 10 10
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR13, SR°, NRI 3R13, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R°;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with 1-3 independent aryl, R or R groups; or Cl-ClO alkenyl substituted with 1-3
7 9 independent aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with 1-3
7 9 independent aryl, R or R groups; Cl-ClO alkenyl substituted with 1-3 independent aryl,
7 9
R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2- C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR R , OC(O)R , Cl-ClO alkyl substituted with 1-3 independent R , halo, CF3, OR12, SR12, N 1 R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12;
19
Each R is independently H; C 1 -C 10 alkyl; C3-C 10 cycloalkyl or phenyl; Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group; and
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl
CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12
12 12 12 12 12 12 12 12 12
S(O)2R ; N(R )C(O)R ; N(R )(COOR ); N(R )S(O)2R ; S(O)2NR R
OC(O)R12; NR1 C(O)NR12R12; NR12C(O)C(O)R'2; NR12C(O)R9; NR12S(O)2NR12R12
NR1 S(O)2R ; NR C(O)C(O)NR' R12; Cl-ClO alkyl substituted with 1-3 independent
R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12,
NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with
1-3 independent R , halo, CF3, OR , SR* , NR1 R , COOR , NO2, CN, C(O)R' ,
C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or 12 .
2. The compound of claim 1 having the formula:
wherein ,
R1 is H; COOR5; C(O)NR5R5; halo; C2-C10 alkyl; Cl-ClO alkenyl; Cl- C10 alkyl substituted with NR R , NR R , SR or OR ; or Cl-ClO alkenyl substituted with NR R , NR R , SR or OR ;
R2 is NR5R15; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl);
5 5 5 5 5 5 16 5 5 6 8
NR -NR C(O)NR R ; NR -NR R ; NR -NR R ; Cl-ClO alkyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
3 4 8 5
R is phenyl substituted with 1-3 independent R ; R ; COOR ; or Cl-ClO
7 8 alkyl substituted with aryl, R or R ;
X is O or S;
4 Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl
CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5
OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5
NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8
NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
9 or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 1 1 1 1 10 10 10 10
NR R . NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; Cl-ClO alkyl substituted with R?, R9
7 9 or aryl; Cl-ClO alkenyl substituted with R , R or aryl; 9
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 11 11 11 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR13, NR13R13, COOR13, NO2, CN, C(O)R13, C(O)NR13R , NHC(O)R!3, or OC(O)R13; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR1 R , COOR , NO2, CN,
C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
11 10 10 10
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R12 is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR13, SR13, NR'V3, COOR13, NO2, CN, C(O)R*3, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
7 9 with one or two independent aryl, R or R groups; or C1-C10 alkenyl substituted with
7 9 aryl, R or R ; Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
7 9 7 9 or two independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R9, halo, CF3, OR12, SR12, NR' 2, COOR12, NO2, CN, C(O)R12, C(O)NR12R'2, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12, Cl-ClO alkyl substituted with R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NRI2R12, OC(O)R12;
Each R is independently H; C 1 -C 10 alkyl; C3-C 10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl; CF3; OR12; SR*2; NR'V2; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR'2R12; S(O)2R12; N(R12)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12; OC(O)R12; NR12C(O)NR12R12; NR12C(O)C(O)R12; NR12C(O)R9; NR1 S(O)2NR12R12; NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR*2, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R12 .
3. The compound of claim 1 having the formula,
wherein,
R is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR -NR R ; NR5-NR5R ; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S;
4 Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl
CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5
OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R
NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R*
NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R7 or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
„9 or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ; 7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R , NR10Rπ, NRnRU, COOR10, NO2, CN, C(O)R10, or C(O)NR10R10 ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl-
C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR*3, SR13, NR13R13, COOR13, NO2, CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN,
C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
11 10 10 10
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- CIO cycloalkenyl, halo, CF3, OR13, SR°, NR' 3, COOR*3, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
14
Each R is each independently selected from Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5 C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5 NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R* NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
7 9 7 9 or two independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR*2, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12, Cl-ClO alkyl substituted with R9, halo, CF3, OR12, SR1 , NR R' , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12;
17
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
19
Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl
12 12 12 12 12 12 12 12 12
CF3; OR ; SR ; NR R ; COOR ; NO2; CN; C(O)R ; C(O)C(O)R ; C(O)NR R S(O)2R12; N(R12)C(O)R12; N(RI2)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12 OC(O)R12; NR12C(O)NR12R12; NR12C(O)C(O)R12; NR12C(O)R9; NR12S(O)2NR12R'2 NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NRI2R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R'2 ;
4 17 14 wherein when all R and R are simultaneously H, R may not be Me, Cl, or OMe; and
14 17 wherein R and R may not simultaneously be Cl.
4. The compound of claim 1 having the formula,
wherein,
R1 is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR -NR5R16; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S;
4
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R8; halo; haloalkyl CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5 OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5 NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8 NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
9 orR ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R ,
10 1 1 11 1 1 10 10 10 10
NR R . NR R , COOR , NO2, CN, C(O)R , or C(O)NR R ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NRV; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; Cl-ClO alkyl substituted with R7, R9
7 9 or aryl; Cl-ClO alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl-
C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
Each R is independently H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; Cl-ClO alkyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR°, NR13R13, COOR13, NO2,
CN, C(O)R , C(O)NR R , NHC(O)R , or OC(O)R ; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR13, SR13, NR'V3, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; 14
Each R is independently selected from Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
16
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10
9 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one
7 9 7 9 or two independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR1 R12, OC(O)R , Cl-ClO alkyl substituted with R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR'2), S(O)2NRI 2R'2,
OC(O)R12;
19 Each R is independently H; C 1 -C 10 alkyl; C3-C 10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl;
CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12;
S(O)2R12; N(R12)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12;
OC(O)R12; NR12C(O)NR12R12; NR*2C(O)C(O)R12; NR12C(O)R9; NR12S(O)2NR12R12; NR S(O)2R9; NR12C(O)C(O)NR12R12; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR'2R12, OC(O)R12; or R12 ;
4 14 wherein when all R are H, R may not be Me or OMe.
5. The compound of claim 1 having the formula,
wherein,
R1 is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR -NR5C(O)NR R ; NR -NR R ; NR -NR R ; Cl-ClO alkyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NRV, NR , COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S;
4 Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl
C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl
CF3; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5
OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5
NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8 NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R? or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
9 or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R , NR'V, NR' Y 1, COOR10, NO2, CN, C(O)R10, or C(O)NR10R10 ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R7, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl-
C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 11 11 11 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
10 Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- CIO cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR13, NR13R13, COOR°, NO2, CN, C(O)R , C(O)NR13R' , NHC(O)R13, or OC(O)R13; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR1 R , COOR , NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
11 10 10 10
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R12 is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-
C10 cycloalkenyl, halo, CF3, OR13, SR13, NR R13, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally
19 19 19 19 19 substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
14
Each R is independently selected from C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR5; OR5; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NRV; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; C1-C10 alkyl substituted with aryl, R? or
8 7 8
R ; or C1-C10 alkenyl substituted with aryl, R or R ;
Each R is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted
7 9 with one or two independent aryl, R or R groups; or C1-C10 alkenyl substituted with
7 9 aryl, R or R ;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; C1-C10 alkyl substituted 7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
17
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo haloalkyl; CFs; SR5; OR5; NR5R5; NRV; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5 C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5 NR5C(O)R5; NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8 NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R7 or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
19
Each R is independently H; Cl-ClO alkyl; C3-C10 cycloalkyl or phenyl;
Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or lO-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12 S(O)2R12; N(R12)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12 OC(O)R12; NR12C(O)NR12R12; NR12C(O)C(O)R12; NR12C(O)R9; NR12S(O)2NR12R12 NR12S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR12R12, NHC(O)R12, H(COOR12), S(O)2NR12R12, OC(O)R12; or R12 ;
14 17 wherein R and R may not simultaneously be Cl.
6. The compound of claim 1 having the formula,
wherein ,
R1 is CN;
R2 is NR5R15; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR -NR C(O)NR R ; NR -NR R ; NR -NR R ; Cl-ClO alkyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NRV, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
R is R ; COOR ; or Cl-ClO alkyl substituted with R , R , or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12, Cl-ClO alkyl substituted with R9, halo, CF3, OR12, SR12, NR'2R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12,
12 3
OC(O)R ; wherein R is not unsubstituted furanyl, unsubstituted thienyl or unsubstituted pyridyl;
X is O or S;
Each R is independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl;
8 C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl;
CF3; SR5; OR5; NR5R5; NR5R6; COOR5; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5;
OC(O)R5; S(O)2R5; S(O)2NR5R5; NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5;
NR5(COOR5); NR5C(O)R8; NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5; NR5C(O)C(O)NR5R6; Cl-ClO alkyl substituted with aryl, R7 or
8 7 8
R ; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R , NR'V, NRΠRU, COOR10, NO2, CN, C(O)R'°, or C(O)NR10R10 ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ; NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 . . Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl-
C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 11 11 11 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ; COOR10; NO2; CN; C(O)R10; or C(O)NR10R10;
10
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- CIO cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R , NHC(O)R' , or OC(O)R ; or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR , SR1 , NR1 R , COOR13, NO2, CN,
C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
11 10 10 10
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR13, SR13, NR13R13, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; Cl-ClO alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with
7 9 aryl, R or R ;
Each R is independently Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10
9 cycloalkyl; C4-C10 cycloalkenyl; R ; Cl-ClO alkyl substituted with one or two
7 9 7 9 independent aryl, R or R groups; Cl-ClO alkenyl substituted with aryl, R or R ; or phenyl substituted with 1-3 independent Cl-ClO alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C 10 cycloalkyl, C4-C10 cycloalkenyl, R9, halo, CF3, OR , SR , NR R12, COOR1 , NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12, Cl-ClO alkyl substituted with R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12;
19
Each R is independently H; C 1 -C 10 alkyl; C3-C 10 cycloalkyl or phenyl; Each haloalkyl is independently a Cl-ClO alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl CF3; OR12; SR12; NR12R12; COOR12; NO2; CN; C(O)R12; C(O)C(O)R12; C(O)NR12R12 S(O)2R12; N(R12)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12 OC(O)R12; NR12C(O)NR12R12; NR12C(O)C(O)R12; NR12C(O)R9; NR12S(O)2NR12R12 NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent R9, halo, CF3, OR12, SR12, NR12R12, COOR12, NO2, CN, C(O)R12, C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; C2-C10 alkenyl substituted with 1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR1 R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R12 .
7. A compound of formula,
wherein,
R2 is NR5R5; SR5; OR5; R8; aryl; N(R5)-N=CH(R8); N(R5)-N=CH(aryl); NR5-NR5C(O)NR5R5; NR5-NR5R15; NR5-NR5R6; Cl-ClO alkyl substituted with aryl, R8, halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR R , or S(O)2NR R ; or Cl-ClO alkenyl substituted with aryl, R , halo, CF3, SR5, OR5, OC(O)R5, NR5R5, NR5R6, COOR5, NO2, CN, C(O)R5, C(O)NR5R5, or S(O)2NR5R5;
X is O or S; 4
R is one, two, or three substituents, each independently selected from H, Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; haloalkyl; CF3; SR ; OR ; NR R ; NR R ; COOR ; NO2; CN; C(O)R5; C(O)C(O)R5; C(O)NR5R5; OC(O)R5; S(O)2R5; S(O)2NR5R5 NR5C(O)NR5R5; NR5C(O)C(O)R5; NR5C(O)R5; NR5(COOR5); NR5C(O)R8 NR5S(O)2NR5R5; NR5S(O)2R5; NR5S(O)2R8; NR5C(O)C(O)NR5R5
NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with aryl, R or R ; or Cl-ClO alkenyl
7 8 substituted with aryl, R or R ;
Each R is independently H; Cl-ClO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; Cl-ClO alkyl substituted
7 9 with one or two independent aryl, R or R groups; C3-C10 cycloalkyl substituted with
7 9 7 one or two independent aryl, R or R groups; or Cl-ClO alkenyl substituted with aryl, R
9 or R ;
Each R is independently C(O)R , COOR , or S(O)2 R ;
7 10 10 10 10 10
Each R is independently halo, CF3, SR , OR , OC(O)R , NR R , NR'V ', NR'V, COOR10, NO2, CN, C(O)R10, or C(O)NRJ V° ;
8
Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R ; halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; OC(O)R ; NR R ; NR R ;
NR6R6; COOR5; NO2; CN; C(O)R5; C(O)NR5R5; C1-C10 alkyl substituted with R?, R9
7 9 or aryl; C1-C10 alkenyl substituted with R , R or aryl;
9 Each R is independently a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from Cl- CIO alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl;
10 10 10 10 10 11 11 11 halo; sulfur; oxygen; CF3; haloalkyl; SR ; OR ; NR R ; NR R ; NR R ;
10 10 10 10
COOR ; NO2; CN; C(O)R ; or C(O)NR R ;
Each R is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3- C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR13, NR^R13, COOR13, NO2, CN, C(O)R , C(O)NR R'^ NHC^R1 , or OC(O)R ; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF3, OR13, SR13, NR13R13, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently C(O)R , COOR , or S(O)2R ;
Each R is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4- C10 cycloalkenyl, halo, CF3, OR13, SR , NR13R13, COOR13, NO2, CN, C(O)R13, C(O)NR13R13, NHC(O)R13, or OC(O)R13;
Each R is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN; or phenyl optionally substituted with halo, CF3, OR , SR , NR R , COOR , NO2, CN;
18 18
Each R is independently C 1 -C 10 alkyl or both R may be taken together
18 as a C2-C7 alkyl chain; wherein any R may optionally be substituted with 1-3
7 8 independent R or R ;
19 Each R is independently H; C1-C10 alkyl; C3-C10 cycloalkyl or phenyl;
Each haloalkyl is independently a C1-C10 alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;
Each aryl is independently a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system optionally substituted with 1-3 independent C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R ; halo; haloalkyl
12 12 12 12 12 12 12 12 12
CF3; OR ; SR ; NR R ; COOR ; NO2; CN; C(O)R ; C(O)C(O)R ; C(O)NR R S(O)2R12; N(R12)C(O)R12; N(R12)(COOR12); N(R12)S(O)2R12; S(O)2NR12R12
12 12 12 12 12 12 12 9 12 12 12
OC(O)R ; NR C(O)NR R ; NR C(O)C(O)R ; NR C(O)R ; NR S(O)2NR R
NR S(O)2R ; NR C(O)C(O)NR R ; Cl-ClO alkyl substituted with 1-3 independent
9 12 12 12 12 12 12 12 12
R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R , C(O)NR R ,
NHC(O)R12, NH(COOR12), S(O)2NR1 R12, OC(O)R12; C2-C10 alkenyl substituted with
1-3 independent R , halo, CF3, OR , SR , NR R , COOR , NO2, CN, C(O)R12,
C(O)NR12R12, NHC(O)R12, NH(COOR12), S(O)2NR12R12, OC(O)R12; or R12 .
8. A composition comprising a compound according to any of claims 1-7 and a pharmaceutically acceptable carrier.
9. The composition according to claim 8, further comprising an additional therapeutic agent.
10. A method of treating a kinase mediated disease or disease symptoms in a mammal comprising administration to said mammal of a compound of claim 1.
11. The method of claim 10, wherein the mammal is a human.
12. A method of inhibiting kinase activity in a mammal comprising the step of administering to said mammal a compound of claim 1.
13. The method of claim 12, wherein said mammal is a human.
14. A method of treating disease or disease symptoms in a mammal comprising the step of administering to said mammal a compound of claim 1.
15. The method of claim 14, wherein said mammal is a human.
I l l
16. A method of making a pharmaceutically useful composition comprising combining a compound of claim 1 with one or more pharmaceutically acceptable carriers.
17. The method of claim 16, further comprising combining an additional therapeutic agent.
18. A method of making a compound of claim 1 comprising reacting a pyrimidinone of the formula:
with an appropriate nucleophilic agent, wherein the groups in said formula are as defined in claim 1.
19. The method of claim 18, wherein R is CN; R is phenyl optionally
4 5 substituted with 1-3 independent R ; X is O; and R is Me.
EP00905700A 1999-01-22 2000-01-21 Kinase inhibitors Withdrawn EP1144390A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11669799P 1999-01-22 1999-01-22
US116697P 1999-01-22
PCT/US2000/001581 WO2000043373A2 (en) 1999-01-22 2000-01-21 Kinase inhibitors

Publications (1)

Publication Number Publication Date
EP1144390A2 true EP1144390A2 (en) 2001-10-17

Family

ID=22368683

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00905700A Withdrawn EP1144390A2 (en) 1999-01-22 2000-01-21 Kinase inhibitors

Country Status (5)

Country Link
EP (1) EP1144390A2 (en)
JP (1) JP2002535318A (en)
AU (1) AU768201B2 (en)
CA (1) CA2359680A1 (en)
WO (1) WO2000043373A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039059D1 (en) 1999-10-07 2008-07-10 Amgen Inc TRIAZINE KINASE INHIBITORS
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
IL156306A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
KR101052482B1 (en) 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 2,4,6-trisubstituted pyrimidine, a phosphatidylinositol (PI) 3-kinase inhibitor, and their use in the treatment of cancer
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
PE20081370A1 (en) * 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME
PE20080839A1 (en) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME
CN101711241A (en) 2007-02-06 2010-05-19 诺瓦提斯公司 PI 3-kinase inhibitors and methods of their use
CA2745165A1 (en) * 2008-12-05 2010-06-10 Merck Sharp & Dohme Corp. Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
CN102206207B (en) * 2011-04-15 2015-05-06 南京邮电大学 4-aryl pyrimidine or 4-heterocyclic aryl pyrimidine compound luminescent material and preparation method thereof
US9221840B2 (en) 2011-05-17 2015-12-29 Discoverybiomed Inc. Treating protein folding disorders with small molecule CFTR correctors
CA2849995A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
WO2014014933A1 (en) * 2012-07-20 2014-01-23 Merck Sharp & Dohme Corp. Hiv treatment with amido-substituted pyrimidinone derivatives
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2891962A1 (en) 2012-11-20 2014-05-03 Discoverybiomed, Inc. Small molecule cftr correctors
US9546176B2 (en) 2012-11-20 2017-01-17 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic CFTR correctors
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3681873A4 (en) * 2017-09-15 2021-05-26 The Regents of the University of California Compositions and methods for inhibiting n-smase2
KR102159277B1 (en) * 2018-11-26 2020-09-23 고려대학교 산학협력단 Use of pyrimidinone derivatives having apoptosis of brain cancer stem cells
CN110105368B (en) * 2019-05-09 2022-01-07 上海大学 Deoxy taxane analogs and preparation method thereof
EP4025216A1 (en) * 2019-09-05 2022-07-13 University of Houston System Small molecule liver x receptor modulators and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1003802A (en) * 1963-06-04 1965-09-08 Searle & Co Pyrimidinone derivatives
DE3008693A1 (en) * 1979-03-19 1980-10-02 Upjohn Co 6-ARYL-PYRIMIDINE COMPOUNDS
US4308272A (en) * 1980-10-03 1981-12-29 The Upjohn Company Process for treating hypertension
HU187355B (en) * 1981-08-28 1985-12-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing 2-amino-4-hydroxy-5-halo-substituted pyrimidine derivatives
GB8410636D0 (en) * 1984-04-26 1984-05-31 Stevens M F G Pharmaceutical substances/compositions
JPS61205260A (en) * 1985-03-08 1986-09-11 Zeria Shinyaku Kogyo Kk Novel 2-substituted amino-6-(2-methoxyphenyl)-4(3h)-pyrimidone derivative and production thereof
US4689328A (en) * 1985-12-31 1987-08-25 Research Corporation Process for controlling hyperlipidemia
JPH0331267A (en) * 1989-06-28 1991-02-12 Morishita Pharmaceut Co Ltd 2-anilino-1,6-dihydro-6-oxo-4-pyrimidine carboxylic acid derivative
WO1997033883A1 (en) * 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
NL1004192C2 (en) * 1996-10-04 1998-04-07 Dsm Nv Supramolecular polymer.
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
EP0948331A2 (en) * 1996-12-12 1999-10-13 PHARMACIA & UPJOHN COMPANY Method for treating multiple sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0043373A2 *

Also Published As

Publication number Publication date
CA2359680A1 (en) 2000-07-27
WO2000043373A3 (en) 2000-12-28
JP2002535318A (en) 2002-10-22
AU2734400A (en) 2000-08-07
AU768201B2 (en) 2003-12-04
WO2000043373A2 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
US6495558B1 (en) Kinase inhibitors
US7282504B2 (en) Kinase inhibitors
AU768201B2 (en) Kinase inhibitors
EP1218360B1 (en) Triazine kinase inhibitors
KR101067254B1 (en) Pyrimidine derivatives as inhibitors of protein kinase and compositions comprising the same
EP1556384B1 (en) Pyrimido compounds having antiproliferative activity
AU2009209633C1 (en) Pyrazine derivatives and their use as protein kinase inhbitors
KR20080066069A (en) Aminopyrimidines useful as kinase inhibitors
AU2006311910A1 (en) Protein kinase inhibitors
MXPA06014247A (en) Compounds and compositions as protein kinase inhibitors.
MX2007011316A (en) Compounds and compositions as protein kinase inhibitors.
MXPA06015147A (en) Compounds and compositions as protein kinase inhibitors.
MXPA01007398A (en) Kinase inhibitors
KR100935273B1 (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010720

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010720;LT PAYMENT 20010720;LV PAYMENT 20010720;MK PAYMENT 20010720;RO PAYMENT 20010720;SI PAYMENT 20010720

17Q First examination report despatched

Effective date: 20030812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050208